Finance

Lists
AQST:NASDAQ
Aquestive Therapeutics Inc
4,63 USD
-0,86%
(-0,040) 1D
4,62 USD
-0,22% (-0,010)
After hours
Closed: 30-сен., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AQST...
Open
4,73 USD
High
4,74 USD
Low
4,62 USD
Mkt. cap
581,12 млн
Avg. vol.
2,73 млн
Volume
2,41 млн
52-wk high
7,55 USD
52-wk low
2,93 USD
EPS
-0,65 USD
Beta
1,48
Shares outstanding
125,51 млн
No. of employees
147
Open
4,73 USD
High
4,74 USD
Low
4,62 USD
Mkt. cap
581,12 млн
Avg. vol.
2,73 млн
Volume
2,41 млн
52-wk high
7,55 USD
52-wk low
2,93 USD
EPS
-0,65 USD
Beta
1,48
Shares outstanding
125,51 млн
No. of employees
147
News stories
From web sources and news partners
About Aquestive Therapeutics Inc
CEO-
Employees147
Founded2004
HeadquartersУоррен, Нью Джерси, Америка Кошмо Штаттары
SectorPharmaceutical industry
Websiteaquestive.com
Analyst ratings
Based on 3 analysts giving stock ratings to AQST in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for AQST in the last 3 months.
Highest
Current 4,63 USD
10,00 USD (+115,98%)
Average
8,67 USD (+87,26%)
Lowest
6,00 USD (+29,59%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Maintained
10,00 USD
+116%
09/21/2026
Francois Brisebois
LifeSci Capital
Buy
Reiterated
10,00 USD
+116%
09/17/2026
Thomas Flaten
Lake Street
Buy
Maintained
6,00 USD
+29,6%
09/17/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
11,00 USD
+137,6%
06/25/2026
Andreas Argyrides
Chardan Capital
Buy
Reiterated
8,00 USD
+72,8%
06/25/2026
Roanna Ruiz
Leerink Partners
Buy
Reiterated
9,00 USD
+94,4%
05/15/2026
David Amsellem
Piper Sandler
Buy
Reiterated
8,00 USD
+72,8%
05/15/2026
James Molloy
Alliance Global Partners
Buy
Maintained
9,00 USD
+94,4%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
12,81 млн
13,02 млн
14,45 млн
13,82 млн
Cost of goods sold
4,51 млн
5,84 млн
3,47 млн
4,02 млн
Cost of revenue
4,51 млн
5,84 млн
3,47 млн
4,02 млн
Research and development expenses
4,53 млн
3,20 млн
4,20 млн
3,96 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15,25 млн
32,82 млн
10,98 млн
14,06 млн
Operating expense
19,78 млн
36,02 млн
15,18 млн
18,02 млн
Total operating expenses
24,29 млн
41,85 млн
18,65 млн
22,04 млн
Operating income
-11,48 млн
-28,84 млн
-4,20 млн
-8,22 млн
Other non operating income
-
-
-
-
EBT including unusual items
-15,45 млн
-31,86 млн
-8,06 млн
-22,86 млн
EBT excluding unusual items
-15,45 млн
-31,86 млн
-8,06 млн
-11,18 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15,45 млн
-31,86 млн
-8,06 млн
-22,86 млн
Net profit margin
-120,61%
-244,79%
-55,77%
-165,45%
Earnings per share
-0,11
-0,14
-0,05
-0,07
Interest and investment income
306,00 миң
1,25 млн
83,00 миң
882,00 миң
Interest expense
-4,27 млн
-4,27 млн
-3,94 млн
-3,84 млн
Net interest expenses
-3,97 млн
-3,02 млн
-3,85 млн
-2,96 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-11,34 млн
-28,68 млн
-4,09 млн
-8,09 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору